Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 163-169

  Palmieri, C ^a,b   Caley, M P ^a   Purshouse, K ^a   Fonseca, A V ^a   Rodriguez Teja, M ^a   Kogianni, G ^a   Woodley, L ^b   Odendaal, J ^b   Elliott, K ^b   Waxman, J ^a   Sturge, J ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Bisphosphonates; bone metastasis; breast cancer; collagen receptor; diagnostic marker; plasma marker

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CA 15-3 ANTIGEN; ENDO180; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; RECEPTORS, MITOGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84872612835     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.540     Document Type: Article

References (29)

1. Behrendt N, Jensen ON, Engelholm LH, Mortz E, Mann M, Dano K (2000) A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem 275(3): 1993-2002.
2. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Biochem 36(1): 2-7.
3. Caley MP, Kogianni G, Adamarek A, Gronau J, Rodriguez-Teja M, Fonseca A-V, Mauri F, Sandison A, Rhim JS, Palmieri C, Cobb J, Waxman J, Sturge J (2011) TGFb1-Endo180 dependent collagen deposition is dysregulated at the tumour-bone stromal interface in bone metastasis. J Path 226(5): 775-783.
4. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6): vi25-vi30.
5. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15): 1396-1405.
6. Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, Behrendt N, Nielsen BS, Bugge TH (2005) Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol 169(6): 977-985.
7. Diamandis EP (2010) Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102(19): 1462-1467.
8. Duffy MJ, Evoy D, McDermott EW (2010) CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 411(23-24): 1869-1874.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
10. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7): 679-691.
11. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7): 631-641.
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33): 5287-5312.
13. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM (2010) A role for fibrillar collagen deposition and the collagen internalization receptor Endo180 in glioma invasion. PLoS One 5(3): e9808.
14. Kogianni G, Walker MM, Waxman J, Sturge J (2009) Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression. Eur J Cancer 45(4): 685-693.
15. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M (2011) Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol 29(27): 3605-3610.
16. Messaritou G, East L, Roghi C, Isacke CM, Yarwood H (2009) Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180. J Cell Sci 122(Part 22): 4042-4048.
17. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20): 1432-1438.
18. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 379(9814): 432-444.
19. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, Huober J, Kramer B, Wackwitz B, Wallwiener D, Fehm T (2012) Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 23(9): 2271-2277.
20. Sturge J, Caley MP, Waxman J (2011) Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 8(6): 357-368.
21. Sturge J, Todd SK, Kogianni G, McCarthy A, Isacke CM (2007) Mannose receptor regulation of macrophage cell migration. J Leukocyte Biol 82(3): 585-593.
22. Sturge J, Wienke D, East L, Jones GE, Isacke CM (2003) GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis. J Cell Biol 162(5): 789-794.
23. Sturge J, Wienke D, Isacke CM (2006) Endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly. J Cell Biol 175(2): 337-347.
24. Sulek J, Wagenaar-Miller RA, Shireman J, Molinolo A, Madsen DH, Engelholm LH, Behrendt N, Bugge TH (2007) Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer. J Histochem Cytochem 55(4): 347-353.
25. Thathiah A, Blobel CP, Carson DD (2003) Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 278(5): 3386-3394.
26. Thathiah A, Carson DD (2004) MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J 382(Part 1): 363-373.
27. Wagenaar-Miller RA, Engelholm LH, Gavard J, Yamada SS, Gutkind JS, Behrendt N, Bugge TH, Holmbeck K (2007) Complementary roles of intracellular and pericellular collagen degradation pathways in vivo. Mol Cell Biol 27(18): 6309-6322.
28. Wienke D, Davies GC, Johnson DA, Sturge J, Lambros MB, Savage K, Elsheikh SE, Green AR, Ellis IO, Robertson D, Reis-Filho JS, Isacke CM (2007) The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res 67(21): 10230-10240.
29. Wienke D, MacFadyen JR, Isacke CM (2003) Identification and characterization of the endocytic transmembrane glycoprotein Endo180 as a novel collagen receptor. Mol Biol Cell 14(9): 3592-3604.